ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies – In head-to-head clinical trials,… Read More
Approximately 300 more people with cystic fibrosis in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time BOSTON, MA… Read More
Getinge and 908 Devices announce their collaboration to integrate Getinge’s bioreactors with 908 Devices’ MAVEN for automated control of glucose and lactate levels in cell cultures. The combined solution will… Read More
CAMBRIDGE, UK, MONTREAL, QB, VANCOUVER, BC & BASEL, CH — Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, and Genevant Sciences, a leading nucleic acid delivery company… Read More
CHARLOTTETOWN, PE – The Canadian Alliance for Skills and Training in Life Sciences (CASTL) is pleased to announce the launch of the CASTL BioWorks Training Program, an initiative funded by Upskill Canada,… Read More
